Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models (Q39184115)
Jump to navigation
Jump to search
scientific article published on 7 March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models |
scientific article published on 7 March 2013 |
Statements
1 reference
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models (English)
1 reference
David Miller
1 reference
Joseph M Gozgit
1 reference
Rachel M Squillace
1 reference
Matthew J Wongchenko
1 reference
Scott Wardwell
1 reference
Qurish Mohemmad
1 reference
Narayana I Narasimhan
1 reference
Frank Wang
1 reference
Tim Clackson
1 reference
Victor M Rivera
1 reference
7 March 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference